ES2774436T3 - Utilización de derivados de pirazolopirimidinas en el tratamiento de trastornos vinculados a PI3K - Google Patents
Utilización de derivados de pirazolopirimidinas en el tratamiento de trastornos vinculados a PI3K Download PDFInfo
- Publication number
- ES2774436T3 ES2774436T3 ES14710739T ES14710739T ES2774436T3 ES 2774436 T3 ES2774436 T3 ES 2774436T3 ES 14710739 T ES14710739 T ES 14710739T ES 14710739 T ES14710739 T ES 14710739T ES 2774436 T3 ES2774436 T3 ES 2774436T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- methyl
- chloro
- compound
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](c1cc(*)c(*)c(*)c1*)Nc1c(C(C)=[N+])c(*)ncn1 Chemical compound C[C@@](c1cc(*)c(*)c(*)c1*)Nc1c(C(C)=[N+])c(*)ncn1 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- MRVLFHBXSHLHOL-UHFFFAOYSA-N CC(c1cc(Cl)c(C)c(-c(cc2)cnc2C(N(C)C)=O)c1OC)[n]1nc(C)c2c(N)nccc12 Chemical compound CC(c1cc(Cl)c(C)c(-c(cc2)cnc2C(N(C)C)=O)c1OC)[n]1nc(C)c2c(N)nccc12 MRVLFHBXSHLHOL-UHFFFAOYSA-N 0.000 description 1
- ONBDXQSSHKXZSF-UHFFFAOYSA-N CC(c1cc(Cl)c(C)c(-c2ccc(C(N(C)CCO)=O)nc2)c1OC)[n]1nc(C)c2c1ncnc2N Chemical compound CC(c1cc(Cl)c(C)c(-c2ccc(C(N(C)CCO)=O)nc2)c1OC)[n]1nc(C)c2c1ncnc2N ONBDXQSSHKXZSF-UHFFFAOYSA-N 0.000 description 1
- KATAAFRJKJMWFE-UHFFFAOYSA-N CC(c1cc(Cl)c(C)c(-c2cncc(C(N(C)C)=O)c2)c1OC)[n]1nc(C)c2c(N)ncnc12 Chemical compound CC(c1cc(Cl)c(C)c(-c2cncc(C(N(C)C)=O)c2)c1OC)[n]1nc(C)c2c(N)ncnc12 KATAAFRJKJMWFE-UHFFFAOYSA-N 0.000 description 1
- CLAWHHQEEYBJHW-UHFFFAOYSA-N CCOc(c(C(C)=O)c1)c(C(CO2)NC2=O)c(F)c1Cl Chemical compound CCOc(c(C(C)=O)c1)c(C(CO2)NC2=O)c(F)c1Cl CLAWHHQEEYBJHW-UHFFFAOYSA-N 0.000 description 1
- IMLHIRHIJBANDD-UHFFFAOYSA-N CCOc(c(C(C)=O)c1)c(C=C)c(F)c1Cl Chemical compound CCOc(c(C(C)=O)c1)c(C=C)c(F)c1Cl IMLHIRHIJBANDD-UHFFFAOYSA-N 0.000 description 1
- ODLPGTJSNVNPJT-UHFFFAOYSA-N CCOc(c(C(C)O)c1)c(C(C2)CNC2=O)c(C#N)c1Cl Chemical compound CCOc(c(C(C)O)c1)c(C(C2)CNC2=O)c(C#N)c1Cl ODLPGTJSNVNPJT-UHFFFAOYSA-N 0.000 description 1
- FBRKRAOGHVCFCB-SFVWDYPZSA-N CCOc(c(C(C)[n]1nc(C)c2c(N)ncnc12)c1)c(C2CN(C[C@H](C)O)C2)c(C)c1Cl Chemical compound CCOc(c(C(C)[n]1nc(C)c2c(N)ncnc12)c1)c(C2CN(C[C@H](C)O)C2)c(C)c1Cl FBRKRAOGHVCFCB-SFVWDYPZSA-N 0.000 description 1
- QNVANHSLAQSVON-UHFFFAOYSA-N CCOc(c(C(CO1)NC1=O)c1F)c(C(C)Cl)cc1Cl Chemical compound CCOc(c(C(CO1)NC1=O)c1F)c(C(C)Cl)cc1Cl QNVANHSLAQSVON-UHFFFAOYSA-N 0.000 description 1
- AWHBRNHVGRVECL-UHFFFAOYSA-N CCOc(c(C(CO1)NC1=O)c1F)c(C(C)O)cc1Cl Chemical compound CCOc(c(C(CO1)NC1=O)c1F)c(C(C)O)cc1Cl AWHBRNHVGRVECL-UHFFFAOYSA-N 0.000 description 1
- UKFAGMZZZSPUFZ-UHFFFAOYSA-N CCOc(c(C1(C)OCCO1)c1)c(C(C2)CNC2=O)c(F)c1Cl Chemical compound CCOc(c(C1(C)OCCO1)c1)c(C(C2)CNC2=O)c(F)c1Cl UKFAGMZZZSPUFZ-UHFFFAOYSA-N 0.000 description 1
- ODJLISKSECPGOQ-UHFFFAOYSA-N CC[O](C)c(c(C(C1)CN1C(C(C)(C)O)=O)c1C#N)c(C(C)[n]2nc(C)c3c2ncnc3N)cc1Cl Chemical compound CC[O](C)c(c(C(C1)CN1C(C(C)(C)O)=O)c1C#N)c(C(C)[n]2nc(C)c3c2ncnc3N)cc1Cl ODJLISKSECPGOQ-UHFFFAOYSA-N 0.000 description 1
- CJNJLCYTPKHVSM-YNODCEANSA-N C[C@H](CN(C1)CC1c(c(C)c(cc1C(C)[n]2nc(C)c3c(N)ncnc23)Cl)c1OC)O Chemical compound C[C@H](CN(C1)CC1c(c(C)c(cc1C(C)[n]2nc(C)c3c(N)ncnc23)Cl)c1OC)O CJNJLCYTPKHVSM-YNODCEANSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771480P | 2013-03-01 | 2013-03-01 | |
| PCT/US2014/019372 WO2014134426A1 (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2774436T3 true ES2774436T3 (es) | 2020-07-21 |
Family
ID=50288319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19208523T Active ES2945212T3 (es) | 2013-03-01 | 2014-02-28 | Utilización de derivados de pirazolopirimidinas para el tratamiento de trastornos relacionados con PI3K |
| ES14710739T Active ES2774436T3 (es) | 2013-03-01 | 2014-02-28 | Utilización de derivados de pirazolopirimidinas en el tratamiento de trastornos vinculados a PI3K |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19208523T Active ES2945212T3 (es) | 2013-03-01 | 2014-02-28 | Utilización de derivados de pirazolopirimidinas para el tratamiento de trastornos relacionados con PI3K |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9932341B2 (OSRAM) |
| EP (3) | EP2961410B1 (OSRAM) |
| JP (5) | JP6545106B2 (OSRAM) |
| KR (5) | KR102454308B1 (OSRAM) |
| CN (2) | CN105120871B (OSRAM) |
| AR (1) | AR094964A1 (OSRAM) |
| AU (5) | AU2014223257B2 (OSRAM) |
| BR (1) | BR112015020941A2 (OSRAM) |
| CA (1) | CA2901993C (OSRAM) |
| CL (1) | CL2015002442A1 (OSRAM) |
| CR (1) | CR20150472A (OSRAM) |
| CY (1) | CY1122712T1 (OSRAM) |
| DK (1) | DK2961410T3 (OSRAM) |
| EA (2) | EA201591612A1 (OSRAM) |
| ES (2) | ES2945212T3 (OSRAM) |
| HR (1) | HRP20200263T1 (OSRAM) |
| HU (1) | HUE047719T2 (OSRAM) |
| IL (6) | IL311666A (OSRAM) |
| LT (1) | LT2961410T (OSRAM) |
| MX (2) | MX367713B (OSRAM) |
| MY (1) | MY177875A (OSRAM) |
| PE (1) | PE20151996A1 (OSRAM) |
| PH (3) | PH12021552233A1 (OSRAM) |
| PL (1) | PL2961410T3 (OSRAM) |
| PT (1) | PT2961410T (OSRAM) |
| RS (1) | RS59958B1 (OSRAM) |
| SG (3) | SG11201506654UA (OSRAM) |
| SI (1) | SI2961410T1 (OSRAM) |
| SM (1) | SMT202000043T1 (OSRAM) |
| TW (5) | TWI657090B (OSRAM) |
| UA (1) | UA119641C2 (OSRAM) |
| WO (1) | WO2014134426A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482278B (zh) | 2009-06-29 | 2015-04-22 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| TWI648277B (zh) | 2011-09-02 | 2019-01-21 | 美商英塞特控股公司 | 作為ｐｉ３ｋ抑制劑之雜環基胺 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| CA2897333C (en) | 2013-01-15 | 2021-07-06 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| CR20160135A (es) | 2013-08-23 | 2016-08-05 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim |
| MY185686A (en) | 2014-04-08 | 2021-05-30 | Incyte Corp | Treatment of b-cell malignancies by a combination jak and p13k inhibitor |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| CA3285092A1 (en) | 2015-02-27 | 2025-11-29 | Incyte Holdings Corporation | Salts of pi3k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| TWI817956B (zh) * | 2017-09-08 | 2023-10-11 | 英屬開曼群島商百濟神州有限公司 | 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑 |
| MD3697789T2 (ro) | 2017-10-18 | 2022-02-28 | Incyte Corp | Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| TWI839788B (zh) | 2018-01-10 | 2024-04-21 | 瑞士商愛杜西亞製藥有限公司 | C5a受體調節劑 |
| RS63124B1 (sr) | 2018-03-08 | 2022-05-31 | Incyte Corp | Aminopirazin diol jedinjenja kao pi3k-y inhibitori |
| CN120053645A (zh) | 2018-06-01 | 2025-05-30 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
| CR20250050A (es) * | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
| TW202329976A (zh) | 2021-12-16 | 2023-08-01 | 美商英塞特公司 | Ｐ１３Ｋ—δ抑制劑之局部調配物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| EP2310391A1 (en) | 2008-06-27 | 2011-04-20 | S*BIO Pte Ltd | Pyrazine substituted purines |
| AR073651A1 (es) | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| AU2010234360A1 (en) | 2009-04-09 | 2011-09-29 | Oncothyreon, Incorporated | Methods and compositions of PI-3 kinase inhibitors for treating fibrosis |
| CN102482278B (zh) | 2009-06-29 | 2015-04-22 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| ES2432315T3 (es) | 2009-08-28 | 2013-12-02 | Takeda Pharmaceutical Company Limited | Compuestos de hexahidrooxazinopterina para su uso como inhibidores de mTOR |
| US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| WO2012106343A2 (en) | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| TWI648277B (zh) * | 2011-09-02 | 2019-01-21 | 美商英塞特控股公司 | 作為ｐｉ３ｋ抑制劑之雜環基胺 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| CA3285092A1 (en) * | 2015-02-27 | 2025-11-29 | Incyte Holdings Corporation | Salts of pi3k inhibitor and processes for their preparation |
| CN120053645A (zh) | 2018-06-01 | 2025-05-30 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| US11161838B2 (en) * | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
-
2014
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en not_active Ceased
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 IL IL311666A patent/IL311666A/en unknown
- 2014-02-28 PH PH1/2021/552233A patent/PH12021552233A1/en unknown
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 SM SM20200043T patent/SMT202000043T1/it unknown
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 KR KR1020247033698A patent/KR20240152422A/ko active Pending
- 2014-02-28 KR KR1020237033761A patent/KR102717616B1/ko active Active
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active Active
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active Active
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920B1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321A1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en not_active Abandoned
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en not_active Abandoned
- 2021-06-30 US US17/364,551 patent/US12152033B2/en active Active
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495B2/en active Active
- 2022-12-01 JP JP2022192954A patent/JP7556010B2/ja active Active
-
2024
- 2024-09-11 JP JP2024157116A patent/JP2025003975A/ja active Pending
- 2024-10-24 US US18/926,010 patent/US20250289823A1/en active Pending
- 2024-12-23 AU AU2024287194A patent/AU2024287194A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2774436T3 (es) | Utilización de derivados de pirazolopirimidinas en el tratamiento de trastornos vinculados a PI3K | |
| ES3036260T3 (en) | Heterocyclylamines as pi3k inhibitors | |
| HK40098131A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| HK40027828A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| HK1221398B (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders |